Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sejal Kothadia is active.

Publication


Featured researches published by Sejal Kothadia.


Journal of Clinical Oncology | 2016

A comparison of patients with liver cancer receiving palliative care at two Veterans Affairs (VA) Medical Centers.

Sarah Lee; Zhen Wang; Sejal Kothadia; Yucai Wang; Ellen Olson; Yeun-Hee Anna Park; David Klein; F. Zhong; Victor Tsu-Shih Chang

75 Background: Liver cancer is a leading cause of death. Lack of data exists on palliative care in this group, and care varies by location. We aim to determine if there are differences in palliative care for patients (pts) with liver cancer by VA site. METHODS In an IRB approved protocol, we reviewed medical records of pts at 2 VA medical centers (S1, S2) with liver cancer, who were seen by Palliative Care between 2006 and 2012. Veterans were compared by 1) demographics: Karnofsky performance status > 50 (KPS), marital status, DNR/DNI, 2) palliative intervention: goals of care discussion, referrals to psychology and PT/OT, and 3) outcomes: ED visit within 1 month (mo) of death, ED visit within 6 mo of death, ICU within 30 days of death, and hospice as site of death, time from diagnosis to palliative care, and time from DNR to death. Chi-square, Fishers Exact, and T-test were performed with Stata. RESULTS here were 82 men, 30 from S1 and 52 from S2, median age 61 (35-87) and 63 (54-88) yrs, respectively. Pts were Caucasian 30 (36%), African American 47 (57%), and other 5 (0.1%). Cancer stages were locoregional 15 (50%), metastatic 13 (43%), and unknown 2 (0.1%) at S1 and 28 (54%), 20 (38%), 5 (0.1%) at S2. Differences were seen in KPS > 50: (S1, S2) [10 (33%), 15(29%) p = 0.010], married: (S1, S2) [7 (23%), 24(46%) p = 0.024], DNR/DNI: (S1, S2) [19 (63%), 13(25%), p = 0.001]. Regarding palliative intervention: goals of care discussion (S1, S2) [26 (87%), 44 (85%), p = 0.044], referral to psych (S1, S2) [16 (53%), 42 (81%) p = 0.014], referral to PT/OT (S1, S2) [17 (57%), 15 (29%), p = 0.007]. Finally in regards to outcome: ED visit within 1 mo of death (S1, S2) [7 (23%), 31 (60%), p = 0.001], ED visit within 6 mos of death (S1, S2) [18 (56%), 35 (67%) p = 0.031], ICU within 30 days of death (S1, S2) [0 (0%), 9 (17%) p = 0.019}, and hospice as site of death (S1, S2) [19 (63%), 21 (40%), p < .0001]. Other key differences included median number of days from diagnosis to initial palliative care consult (S1, S2) [97, 39, p = 0.001] and median number of days from DNR to death (S1, S2) [33, 14, p = 0.001]. CONCLUSIONS Results show there are site-specific differences between VA medical centers. These data may be important in the comparison of other centers and provide a baseline for future studies.


Journal of Clinical Oncology | 2016

Palliative care interventions and end-of-life care outcomes for hepatocellular patients (pts) at two Veterans Affairs (VA) medical centers.

Zhen Wang; Sarah Lee; Sejal Kothadia; Yucai Wang; Victor Tsu-Shih Chang; Yeun-Hee Anna Park; Ellen Olson; David Klein; F. Zhong

164 Background: Palliative care interventions and their effect on EOL outcomes for liver cancer pts have not been described. We investigated the association between palliative care intervention and EOL care outcomes. METHODS We reviewed the charts of pts with hepatocellular carcinoma and who were seen by palliative care at 2 VA medical centers from 2006 to 2012. We investigated the association between EOL outcomes (number of ER visits, ICU visits, chemotherapy, place of death, number of hospitalizations during their last 30 days), and interventions such as early referral (within 30 days of diagnosis), defined goals of care, holding a family meeting, and symptom assessment and management. The protocol was reviewed by the IRB of both VAs and analyses were done with SAS Studio v3.4. RESULTS 82 charts were reviewed (30 from EOVA and 52 from BVA). All Pts were men; 30 (39%) were white and 47(61%) African American. Interval from diagnosis to palliative care consult was 68 days (median). 72 (90%) pts were not aware of their diagnosis. 48 (65%) were not aware of prognosis. 65 (88%) had decision making capacity. 32 (39%) pts were DNR/DNI. 60 (86%) pts chose symptom management and 10 (14%) life prolongation. 47 pts (50%) had family meeting. In the last month, 35 pts (48%) had ER visit. 9 pts (12%) had ICU visits, 4 pts (5%) had chemotherapy and 48 pts (71%) had at least 1 hospitalization. 68 (85%) underwent symptom assessment. Most frequently treated symptoms were pain (78%), nausea (27%), constipation (46%), dyspnea (34%). Significant associations were found for early referral and ER admissions (OR = 3.2, p = 0.0178), family meeting and site of death (OR = 0.136 p = 0.0037), family meeting and number of hospitalizations (OR = 0.2652, p = 0.0169). Pts choosing symptom management and who had family meetings associated with hospice/home as place of death (chisq = 5.7368, p = 0.016). Knowledge of prognosis was not associated with site of death. CONCLUSIONS In this population, many palliative care interventions were performed. Early referral, family meetings were significantly associated with site of death, ER admissions, and number of hospitalizations. These results should be replicated in larger studies.


Journal of Clinical Oncology | 2016

Too sick to enroll? Comorbidities limiting recruitment in early phase trials, review of over 1,100 clinical trials.

Narjust Duma; Sejal Kothadia; Zhen Wang; Sarah Lee; Jesyree Veitia Campos; Bryant Van Leeuwen; Ramya Undamatla; Ricardo Daniel Parrondo; Komal Patel; Rima Panchal; Marshall McKenna; Veronica Mariotti; Jieqi Liu; Miguel Gonzalez Velez; Brittany Gladney; Larysa Sanchez; Shijia Zhang; Martin Gutierrez


Journal of Clinical Oncology | 2018

Comprehensive analysis of tumor mutational load, genomic alterations, and PD-L1 status in gastrointestinal cancers using a multiplatform molecular profiling tool.

Giselle Alexandra Suero-Abreu; Miguel Gonzalez Velez; Marshall McKenna; Narjust Duma; Sejal Kothadia; Shalini R. Krishnasamy; Janice Liu; Ning Dong; Umar Sharif Khawaja; Daniel Pievsky; Tracy Ann Proverbs-Singh; Martin Gutierrez


Journal of Clinical Oncology | 2017

Comparison of palliative care for lung cancer patients (pts) at two Veteran Affairs Medical Centers.

Sejal Kothadia; Zhen Wang; Sarah Lee; Victor Tsu-Shih Chang; Yeun-Hee Anna Park; Ellen Olson; David Klein; Andrea Nadine Leaf; Stephanie Hwa; F. Zhong


Journal of Clinical Oncology | 2017

A comparison of liver cancer and lung cancer patients at two Veteran Affairs Medical Centers.

Sejal Kothadia; Zhen Wang; Sarah Lee; Victor Tsu-Shih Chang; Yucai Wang; Yeun-Hee Anna Park; Ellen Olson; David Klein; Andrea Nadine Leaf; Stephanie Hwa; F. Zhong


Journal of Clinical Oncology | 2017

Comorbidities limiting recruitment of colorectal cancer (CRC) patients in early-phase trials.

Narjust Duma; Yucai Wang; Miguel Gonzalez Velez; Sejal Kothadia; Veronica Mariotti; Ricardo Daniel Parrondo; Joleen M. Hubbard; Alex A. Adjei; Thorvardur R. Halfdanarson


Journal of Clinical Oncology | 2017

Genomic-directed therapy of gastrointestinal cancers by comprehensive genomic profile (CGP): Clinical and genomic characteristics at the John Theurer Cancer Center (JTCC).

Miguel Gonzalez Velez; Narjust Duma; Valentina Jaramillo Restrepo; Pablo Lopez-Zertuche; Ricardo Daniel Parrondo; Veronica Mariotti; Sejal Kothadia; Beth Boseski; Andrew Jennis; Martin Gutierrez


Journal of Clinical Oncology | 2017

Analysis of clinical and research implications of expanding next-generation sequencing (NGS) libraries in the treatment options of gastrointestinal cancers in a large cancer center.

Miguel Gonzalez Velez; Narjust Duma; Valentina Jaramillo Restrepo; Pablo Lopez-Zertuche; Sejal Kothadia; Veronica Mariotti; Ricardo Daniel Parrondo; Beth Boseski; Andrew Jennis; Martin Gutierrez


European Journal of Cancer | 2017

Early phase clinical trials conducted in North America are more likely to exclude breast cancer patients based on organ function and comorbidities compared to other countries: Analysis of 484 studies

Veronica Mariotti; M. Gonzalez Velez; Narjust Duma; Ricardo Daniel Parrondo; Sejal Kothadia; Brittany Gladney; Rima Panchal; Jieqi Liu; Komal Patel; Ramya Undamatla

Collaboration


Dive into the Sejal Kothadia's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Gutierrez

Hackensack University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Victor Tsu-Shih Chang

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge